Literature DB >> 27628189

Bradykinin -induced vasodilatation: Role of age, ACE1-inhibitory peptide, mas- and bradykinin receptors.

A Siltari1, R Korpela2, H Vapaatalo2.   

Abstract

Bradykinin exerts its vascular actions via two types of receptors, the non-constitutively expressed bradykinin receptor type 1 (BR1) and the constitutive type 2 receptor (BR2). Bradykinin-induced vasorelaxation is age-dependent, a phenomenon related to the varying amounts of BR1 and BR2 in the vasculature. Isoleucine-proline-proline (Ile-Pro-Pro), a bioactive tripeptide, lowers elevated blood pressure and improves impaired endothelium-dependent vasorelaxation in hypertensive rats. It inhibits angiotensin converting enzyme 1 (ACE1). Other mechanisms of action have also been postulated. The aims of the study were to clarify the underlying mechanisms of the age-dependency of bradykinin-induced vasodilatation such as the roles of the two bradykinin receptors, the mas-receptor and synergism with Ile-Pro-Pro. The vascular response studies were conducted using mesenteric artery and aorta rings from normotensive 6 wk. (young) and 22 wk. (old) Wistar rats. Cumulative dosing of acetylcholine, bradykinin and angiotensin(1-7) (Ang(1-7))were tested in phenylephrine-induced vasoconstriction with or without 10min pre-incubation with antagonists against BR1-, BR2- or mas-receptors, Ang(1-7) or ACE1-inhibitors captopril and Ile-Pro-Pro. The bradykinin-induced vasorelaxation in vitro was age-dependent and it was improved by pre-incubation with Ile-Pro-Pro, especially in old rats with endothelial dysfunction. The mas-receptor antagonist, D-Pro7-Ang(1-7) abolished bradykinin-induced relaxation totally. Interestingly, BR1 and BR2 antagonists only slightly reduced bradykinin-induced vasorelaxation, as an evidence for the involvement of other mechanisms in addition to receptor activation. In conclusion, bradykinin-induced vasorelaxation was age-dependent and Ile-Pro-Pro improved it. Mas receptor antagonist abolished relaxation while bradykinin receptor antagonist only slightly reduced it, suggesting that bradykinin-induced vasorelaxation is regulated also by other mechanisms than the classical BR1/BR2 pathway.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACE-inhibition; Ageing; Bioactive peptides; Bradykinin; Ile-Pro-Pro; Vascular function; Vasodilatation

Mesh:

Substances:

Year:  2016        PMID: 27628189     DOI: 10.1016/j.peptides.2016.09.001

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  5 in total

1.  A score for the differential diagnosis of bradykinin- and histamine-induced head and neck swellings.

Authors:  M Lenschow; M Bas; F Johnson; M Wirth; U Strassen
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-02       Impact factor: 2.503

Review 2.  Structural Mechanisms of Store-Operated and Mitochondrial Calcium Regulation: Initiation Points for Drug Discovery.

Authors:  Megan Noble; Qi-Tong Lin; Christian Sirko; Jacob A Houpt; Matthew J Novello; Peter B Stathopulos
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

Review 3.  The Contribution of Gut Microbiota and Endothelial Dysfunction in the Development of Arterial Hypertension in Animal Models and in Humans.

Authors:  Jessica Maiuolo; Cristina Carresi; Micaela Gliozzi; Rocco Mollace; Federica Scarano; Miriam Scicchitano; Roberta Macrì; Saverio Nucera; Francesca Bosco; Francesca Oppedisano; Stefano Ruga; Anna Rita Coppoletta; Lorenza Guarnieri; Antonio Cardamone; Irene Bava; Vincenzo Musolino; Sara Paone; Ernesto Palma; Vincenzo Mollace
Journal:  Int J Mol Sci       Date:  2022-03-28       Impact factor: 5.923

4.  A Role of Inflammation and Immunity in Essential Hypertension-Modeled and Analyzed Using Petri Nets.

Authors:  Dorota Formanowicz; Agnieszka Rybarczyk; Marcin Radom; Piotr Formanowicz
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

Review 5.  Does eNOS derived nitric oxide protect the young from severe COVID-19 complications?

Authors:  Shou Ping Guan; Raymond Chee Seong Seet; Brian K Kennedy
Journal:  Ageing Res Rev       Date:  2020-11-04       Impact factor: 10.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.